Epigenome-wide association studies (EWAS) in cancer

Current Genomics

Volumn 13, Issue 4, 2012, Pages 308-313

  Verma, Mukesh ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Acetylation; Assessment; Biomarker; Chromatin; Environmental mutagens; Epidemiology; Epigenetics; Histone; Histone acetyl transferase (HAT); Histone code; Histone deacetylase (HDAC); Screening

Indexed keywords

ARTICLE; CANCER GROWTH; CLINICAL PRACTICE; ENVIRONMENT; EPIGENETICS; GENE SEQUENCE; GENE STRUCTURE; GENETIC ASSOCIATION; GENOME; GLIOMA; HEAD AND NECK CANCER; HISTONE MODIFICATION; HUMAN; METHYLATION; NEOPLASM; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84862636255     PISSN: 13892029     EISSN: 18755488     Source Type: Journal    
DOI: 10.2174/138920212800793294     Document Type: Article

References (47)

1. Esteller, M. Epigenetics in cancer. N. Engl. J. Med., 2007, 358, 1148-1159.
2. Sharma S.; Kelly T.K.; Jones P.A. Epigenetics in cancer. Carcinogenesis, 2010, 31, 27-36.
3. Merkel, O.; Hamacher, F.; Laimer, D.; Sifft, E.; Trajanoski, Z.; Scheideler, M.; Egger, G.; Hassler, M.R.; Thallinger, C.; Schmatz, A.; Turner, S.D.; Greil, R.; Kenner, L. Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma. Proc. Natl. Acad. Sci. USA, 2010, 107, 16228-16233.
4. Mishra, P.J.; Bertino, J.R. MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine. Pharmacogenomics, 2009, 10, 399-416.
5. Hede, K. Imprinting may provide cancer prevention tools. J. Natl. Cancer Inst., 2007, 99, 424-426.
6. Jones, P.A.; Baylin, S.B. The epigenomics of cancer. Cell, 2007, 128, 683-692.
7. Verma, M.; Seminara, D.; Arena, F.J.; John, C.; Iwamoto, K.; Hartmuller, V. Genetic and epigenetic biomarkers in cancer: improving diagnosis, risk assessment, and disease stratification. Mol. Diagn. Ther., 2006, 10, 1-15.
8. Huang, T.H.; Esteller, M. Chromatin remodeling in mammary gland differentiation and breast tumorigenesis. Cold Spring Harb. Perspect. Biol., 2010, 2, a004515.
9. Peterson, C. L.; Laniel, M.A. Histones and histone modifications. Curr. Biol., 2004, 14, 546-551.
10. Jiang, Y.H.; Bressler, J.; Beauder, A.L. Epigenetics and human disease. Annu. Rev. Genomics Hum. Genet., 2004, 5, 479-510.
11. Wild, C.P. Environmental exposure measurement in cancer epidemiology. Mutagenesis, 2009, 24, 117-125.
12. Jaenisch, R.; Bird, A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat. Genet., 2003, 33, 245-253.
13. Ozanne, S.E.; Constancia, M. Mechanisms of disease: the developmental origins of disease and the role of the epigenotype. Nat. Clin. Pract. Endocrinol. Metab., 2007, 3, 539-546.
14. Feinberg, A. Epigenetics at the epicenter of modern medicine. JAMA, 2008, 299, 1345-1350.
15. Cammarata, G.; Augugliaro, L.; Salemi, D.; Agueli, C.; La Rosa, M.; Dagnino, L.; Civiletto, G.; Messana, F.; Marfia, A.; Bica, M.G.; Cascio, L.; Floridia, P.M.; Mineo, A. M.; Russo, M.; Fabbiano, F.; Santoro, A. Differential expression of specific microRNA and their targets in acute myeloid leukemia. Am. J. Hematol., 2010, 85, 331-339.
16. Häusler, S.F.; Keller, A.; Chandran, P.A.; Ziegler, K.; Zipp, K.; Heuer, S.; Krockenberger, M.; Engel, J.B.; Hönig, A.; Scheffler, M.; Dietl, J.; Wischhusen, J. Whole blood-derived miRNA profiles as potential n ew tools for ovarian cancer screening. Br. J. Cancer, 2010, 103, 693-700.
17. Vaissière, T.; Cuenin, C.; Paliwal, A.; Vineis, P.; Hainaut, P.; Herceg, Z. Quantitative analysis of DNA methylation after whole bisulfitome amplification of a minute amount of DNA from body fluids. Epigenetics, 2009, 4, 221-230.
18. Montserrat, E.; Moreno, C. Genetic lesions in chronic lymphocytic leukemia: clinical implications. Curr. Opin. Oncol., 2009, 21, 609-614.
19. Yu, Y.; Blair, S.; Gillespie, D.; Jensen, R.; Myszka, D.; Badran, A.H.; Ghosh, I.; Chagovetz, A. Direct DNA methylation profiling using methyl binding domain proteins. Anal. Chem., 2010, 82, 5012-5019.
20. Estecio, M.R.; Yan, P.S.; Ibrahim, A.E.; Tellez, C.S.; Shen, L.; Huang, T.H.; and Issa, J. P. High-throughput methylation profiling by MCA coupled to CpG island microarray. Genome Res., 2007, 17, 1529-1536.
21. Hoque, M.O.; Kim, M.S.; Ostrow, K.L.; Liu, J.; Wisman, G.B.; Park, H.L.; Poeta, M.L.; Jeronimo, C.; Henrique, R.; Lendvai, A.; Schuuring, E.; Begum, S.; Rosenbaum, E.; Ongenaert, M.; Yamashita, K.; Califano, J.; Westra, W.; van der Zee, A.G.; Van Criekinge, W.; Sidransky, D. Genome-wide promoter analysis uncovers portions of the cancer methylome. Cancer Res., 2008, 68, 2661-2670.
22. Muller, H.M.; Oberwalder, M.; Fiegl, H.; Morandell, M.; Goebel, G.; Zitt, M.; Muhlthaler, M.; Ofner, D.; Margreiter, R.; Widschwendter, M. Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet, 2004, 363, 1283-1285.
23. Ogino, S.; Odze, R.D.; Kawasaki, T.; Brahmandam, M.; Kirkner, G.J.; Laird, P.W.; Loda, M.; Fuchs, C.S. Correlation of pathologic features with CpG island methylator phenotype (CIMP) by quantitative DNA methylation analysis in colorectal carcinoma. Am. J. Surg. Pathol., 2006, 30, 1175-1183.
24. Gao, F.H.; Hu, X.H.; Li, W.; Liu, H.; Zhang, Y.J.; Guo, Z.Y.; Xu, M.H.; Wang, S.T.; Jiang, B.; Liu, F.; Zhao, Y.Z.; Fang, Y.; Chen, F.Y.; Wu, Y.L. Oridonin induces apoptosis and senescence in colorectal cancer cells by increasing histone hyperacetylation and regulation of p16, p21, p27 and c-myc. BMC Cancer, 2010, 10, 610.
25. Park, J.Y. Promoter hypermethylation in prostate cancer. Cancer Control, 2010, 17, 245-255.
26. Nebert, D.W. Given the complexity of human genome, can "personalized medicine" or "individualized drug therapy" ever be achieved? Hum. Genomics, 2009, 3, 299-300.
27. Nebert, D.W. Extreme discordant phenotype methodology: an intuitive approach to clinical pharmacogenetics. Eur. J. Pharmacol., 2000, 410, 107-120.
28. Nebert, D.W.; Dalton, T.P. The role of cytochrome P450 enzymes in endogenous signal pathways and environmental carcinogenesis. Nat. Rev. Cancer, 2006, 6, 947-960.
29. Nebert, D.W.; Gálvez-Peralta, M.; Shi, Z.; Dragin, N. Inbreeding and epigenetics: beneficial as well as deleterious effects. Nat. Rev. Genet., 2010, 11, 662-664.
30. Zhang, G.; Nebert, D.W.; Chakraborty, R.; Jin, L. Statistical power of association using the extreme discordant phenotype design. Pharmacogenet. Genomics, 2006, 16, 401-413.
31. Liu, B.L.; Cheng, J.X.; Zhang, X.; Wang, R.; Zhang, W.; Lin, H.; Xiao, X.; Cai, S.; Chen, X.Y.; Cheng, H. Global histone modification patterns as prognostic markers to classify glioma patients. Cancer Epidemiol. Biomarkers Prev, 2010, 19, 2888-2896.
32. Bhandare, R.; Schug, J.; Le, L.J.; Fox, A.; Smirnova, O.; Liu, C.; Naji, A.; Kaestner, K. H. Genome-wide analysis of histone modifications in human pancreatic islets. Genome Res., 2010, 20, 428-433.
33. Jin, Z.; Cheng, Y.; Gu, W.; Zheng, Y.; Sato, F.; Mori, Y.; Olaru, A.V.; Paun, B.C.; Yang, J.; Kan, T.; Ito, T.; Hamilton, J.P.; Selaru, F.M.; Agarwal, R.; David, S.; Abraham, J.M.; Wolfsen, H.C.; Wallace, M.B.; Shaheen, N.J.; Washington, K.; Wang, J.; Canto, M.I.; Bhattacharyya, A.; Nelson, M.A.; Wagner, P.D.; Romero, Y.; Wang, K.K.; Feng, Z.; Sampliner, R.E.; Meltzer, S.J. A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus. Cancer Res., 2009, 69, 4112-4115.
34. Sato, F.; Jin, Z.; Schulmann, K.; Wang, J.; Greenwald, B.D.; Ito, T.; Kan, T.; Hamilton, J.P.; Yang, J.; Paun, B.; David, S.; Olaru, A.; Cheng, Y.; Mori, Y.; Abraham, J.M.; Yfantis, H.G.; Wu, T.T.; Fredericksen, M.B.; Wang, K.K.; Canto, M.; Romero, Y.; Feng, Z.; Meltzer, S.J. Three-tiered risk stratification model to predict progression in Barrett's esophagus using epigenetic and clinical features. PLoS One, 2008, 3, e1890.
35. Boffetta, P.; Stellman, S.D.; Garfinkel, L. A case-control study of multiple myeloma nested in the American Cancer Society prospective study. Int. J. Cancer, 1989, 43, 554-559.
36. Boffetta, P.; McLaughlin, J.K.; La Vecchia, C.; Autier, P.; Boyle, P. Environment in cancer causation and etiological fraction: limitation and ambiguities. Carcinogenesis, 2007, 28, 913-915.
37. Baris, D.; Brown, L.M.; Silverman, D.T.; Hayes, R.; Hoover, R.N.; Swanson, G.M.; Dosemeci, M.; Schwartz, A.G.; Liff, J.M.; Schoenberg, J.B.; Pottern, L.M.; Lubin, J.; Greenberg, R.S.; Fraumeni, J.F. Jr. Socioeconomic status and multiple myeloma among US blacks and whites. Am. J. Public Health, 2002, 90, 1277-1281.
38. Brown, L.M.; Linet, M.S.; Greenberg, R.S.; Silverman, D.T; Hayes, R.B; Swanson, G. M.; Schwartz, A. G.; Schoenberg, J. B.; Pottern, L. M.; Fraumeni, J.F. Jr. Multiple myeloma and family history of cancer among blacks and whites in the U.S. Cancer, 1999, 85, 2385-2390.
39. Saracci, R.; Vineis, P. Disease proportions attributable to environment. Environ. Health, 2007, 6, 38.
40. Pruss-Ustun, A.; Corvalan, C. Preventing Disease Through Health Environments. Towards an Estimate of the Environmental Burden of Disease. World Health Organization: Geneva, Switzerland, 2006.
41. Michels, K.B. Nutritional epidemiology-past, present, future. Int. J. Epidemiol., 2003, 32, 486-488.
42. Michels, K.B. The promises and challenges of epigenetic epidemiology. Exp. Gerontol., 2010, 45, 297-301.
43. Waterland, R.A.; Michels, K.B. Epigenetic epidemiology of the developmental origins hypothesis. Annu. Rev. Nutr., 2007, 27, 363-388.
44. Aparicio, A.; North, B.; Barske, L. Wang, X.; Bollati, V.; Weisenberger, D.; Yoo, C.; Tannir, N.; Horne, E.; Groshen, S.; Jones, P.; Yang, A.; Issa, J.P. LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors. Epigenetics, 2009, 4, 176-184.
45. Szaumkessel, M.; Richter, J.; Giefining, M.; Jarmuz, M.; Kiwerska, K.; Tönnies, H.; Grenman, R.; Heidemann, S.; Szyfter, K.; Siebert, R. Pyrosequencing-based DNA methylation profiling of Fanconi anemia/BRCA pathway genes in laryngeal squamous cell carcinoma. Int. J.Oncol., 2011, 39, 505-514.
46. Mathers, J.C.; StrathDee, G.; Relton, C.L. Induction of epigenetic alterations by dietary and other environmental factors. Adv. Genet., 2010, 71, 3-39.
47. Ohkawa, Y.; Mallappa, C.; Vallaster, C.S.; Imbalzano, A.N. Isolation of nuclei from skeletal muscle satellite cells and myofibers for use in chromatin immunoprecipitation assays. Methods Mol. Biol., 2012, 798, 517-530.